Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chongfei Huang

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 9, 2026
Gut Microbiome Dysbiosis Promotes Gallstone Formation via Bile Acid Metabolic Disorder: A Multiomics StudyChongfei Huang, Weijun Xiao, Jinyu Zhao, et al.
Preventive Medicine|March 28, 2024
Genetic risk, adherence to healthy lifestyle behaviors, and risk of cholelithiasis: A population-based cohort studyNingning Mi, Zixin Liang, Man Yang, et al.
Human Cell|November 15, 2023
Establishment and characterization of a novel hilar cholangiocarcinoma cell line, CBC3T-1Mingzhen Bai, Ningzu Jiang, Wenkang Fu, et al.
Frontiers in Pharmacology|August 2, 2023
Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiotaLiang Tian, Chongfei Huang, Wenkang Fu, et al.
Human Cell|April 1, 2026
CBC3T-3: a novel patient-derived cisplatin-resistant distal cholangiocarcinoma cell line harboring multiple TP53 missense mutationsJiahui Xi, Mingzhen Bai, Ruyang Zhong, et al.
International Journal of Cancer|May 26, 2023
Confounded association between proton pump inhibitor use and risk of biliary tract cancer: Result from three cohortsQiangsheng He, Chongfei Huang, Xiwen Qin, et al.
Scientific Reports|November 29, 2024
Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6Mingzhen Bai, Ruoshui Wang, Chongfei Huang, et al.
Pharmacological Research|August 1, 2024
Design of the distribution of iron oxide (Fe<sub>3</sub>O<sub>4</sub>) nano-particle drug in realistic cholangiocarcinoma model and the simulation of temperature increase during magnetic induction hyperthermiaYawen Lu, Chongfei Huang, WenKang Fu, et al.
BMC Cancer|January 4, 2024
Regular use of paracetamol and risk of liver cancer: a prospective cohort studyLiang Tian, Ningning Mi, Leiqing Wang, et al.
Acta Pharmaceutica Sinica. B|September 23, 2024
Beyond ribosomal function: RPS6 deficiency suppresses cholangiocarcinoma cell growth by disrupting alternative splicingWenkang Fu, Yanyan Lin, Mingzhen Bai, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|March 9, 2026
Gut Microbiome Dysbiosis Promotes Gallstone Formation via Bile Acid Metabolic Disorder: A Multiomics StudyChongfei Huang, Weijun Xiao, Jinyu Zhao, et al.
Preventive Medicine|March 28, 2024
Genetic risk, adherence to healthy lifestyle behaviors, and risk of cholelithiasis: A population-based cohort studyNingning Mi, Zixin Liang, Man Yang, et al.
Human Cell|November 15, 2023
Establishment and characterization of a novel hilar cholangiocarcinoma cell line, CBC3T-1Mingzhen Bai, Ningzu Jiang, Wenkang Fu, et al.
Frontiers in Pharmacology|August 2, 2023
Proton pump inhibitors may enhance the risk of digestive diseases by regulating intestinal microbiotaLiang Tian, Chongfei Huang, Wenkang Fu, et al.
Human Cell|April 1, 2026
CBC3T-3: a novel patient-derived cisplatin-resistant distal cholangiocarcinoma cell line harboring multiple TP53 missense mutationsJiahui Xi, Mingzhen Bai, Ruyang Zhong, et al.
International Journal of Cancer|May 26, 2023
Confounded association between proton pump inhibitor use and risk of biliary tract cancer: Result from three cohortsQiangsheng He, Chongfei Huang, Xiwen Qin, et al.
Scientific Reports|November 29, 2024
Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6Mingzhen Bai, Ruoshui Wang, Chongfei Huang, et al.
Pharmacological Research|August 1, 2024
Design of the distribution of iron oxide (Fe<sub>3</sub>O<sub>4</sub>) nano-particle drug in realistic cholangiocarcinoma model and the simulation of temperature increase during magnetic induction hyperthermiaYawen Lu, Chongfei Huang, WenKang Fu, et al.
BMC Cancer|January 4, 2024
Regular use of paracetamol and risk of liver cancer: a prospective cohort studyLiang Tian, Ningning Mi, Leiqing Wang, et al.
Acta Pharmaceutica Sinica. B|September 23, 2024
Beyond ribosomal function: RPS6 deficiency suppresses cholangiocarcinoma cell growth by disrupting alternative splicingWenkang Fu, Yanyan Lin, Mingzhen Bai, et al.
Pageof 3